Limits...
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.

Chang YH, Lu CH, Yen MS, Lee WH, Chang Y, Chang WP, Chuang CM - Chin J Cancer (2016)

Bottom Line: Two propensity score-matched sample cohorts were created.We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen.If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

View Article: PubMed Central - PubMed

Affiliation: Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, 11221, Taiwan, China.

ABSTRACT
We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

No MeSH data available.


Related in: MedlinePlus

Flow chart of the screening and propensity score-matching process
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4862156&req=5

Fig1: Flow chart of the screening and propensity score-matching process

Mentions: We collected the clinical data of patients with stage III epithelial ovarian, tubal, and peritoneal cancer between January 2002 and December 2012 who were treated in the Institutional Review Board of Taipei Veterans General Hospital. Patients in the control cohort were treated according to the protocol described in the GOG 114 trial [1]; patients in the experimental cohort were treated according to the protocol described in the GOG 172 trial [2]. A flow chart describing the screening and matching process is shown in Fig. 1.Fig. 1


Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.

Chang YH, Lu CH, Yen MS, Lee WH, Chang Y, Chang WP, Chuang CM - Chin J Cancer (2016)

Flow chart of the screening and propensity score-matching process
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4862156&req=5

Fig1: Flow chart of the screening and propensity score-matching process
Mentions: We collected the clinical data of patients with stage III epithelial ovarian, tubal, and peritoneal cancer between January 2002 and December 2012 who were treated in the Institutional Review Board of Taipei Veterans General Hospital. Patients in the control cohort were treated according to the protocol described in the GOG 114 trial [1]; patients in the experimental cohort were treated according to the protocol described in the GOG 172 trial [2]. A flow chart describing the screening and matching process is shown in Fig. 1.Fig. 1

Bottom Line: Two propensity score-matched sample cohorts were created.We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen.If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

View Article: PubMed Central - PubMed

Affiliation: Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, 11221, Taiwan, China.

ABSTRACT
We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

No MeSH data available.


Related in: MedlinePlus